Zacks: Analysts Anticipate Catalyst Pharmaceuticals Inc (CPRX) Will Announce Earnings of -$0.08 Per Share

Wall Street brokerages predict that Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) will announce earnings of ($0.08) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Catalyst Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.09) and the highest estimate coming in at ($0.06). Catalyst Pharmaceuticals posted earnings per share of ($0.05) during the same quarter last year, which indicates a negative year-over-year growth rate of 60%. The company is expected to report its next earnings report on Wednesday, August 8th.

According to Zacks, analysts expect that Catalyst Pharmaceuticals will report full-year earnings of ($0.35) per share for the current year, with EPS estimates ranging from ($0.39) to ($0.25). For the next financial year, analysts anticipate that the firm will post earnings of ($0.08) per share, with EPS estimates ranging from ($0.12) to ($0.03). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that cover Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.06).

A number of brokerages have commented on CPRX. Oppenheimer began coverage on Catalyst Pharmaceuticals in a research note on Thursday, July 12th. They issued a “buy” rating and a $6.00 price target on the stock. ValuEngine raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, May 14th. Finally, BidaskClub raised Catalyst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average target price of $6.20.

Shares of Catalyst Pharmaceuticals stock opened at $3.05 on Thursday. Catalyst Pharmaceuticals has a one year low of $2.18 and a one year high of $4.51.

In other Catalyst Pharmaceuticals news, Director Donald A. Denkhaus acquired 20,000 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were purchased at an average cost of $3.75 per share, for a total transaction of $75,000.00. Following the transaction, the director now owns 120,000 shares in the company, valued at $450,000. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders bought 29,000 shares of company stock worth $106,940. Corporate insiders own 9.60% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Two Sigma Securities LLC grew its position in shares of Catalyst Pharmaceuticals by 132.2% in the 4th quarter. Two Sigma Securities LLC now owns 26,658 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 15,178 shares during the last quarter. Tanaka Capital Management Inc. grew its position in shares of Catalyst Pharmaceuticals by 6.4% in the 4th quarter. Tanaka Capital Management Inc. now owns 256,593 shares of the biopharmaceutical company’s stock worth $1,003,000 after buying an additional 15,515 shares during the last quarter. California State Teachers Retirement System grew its position in shares of Catalyst Pharmaceuticals by 18.2% in the 1st quarter. California State Teachers Retirement System now owns 133,262 shares of the biopharmaceutical company’s stock worth $318,000 after buying an additional 20,484 shares during the last quarter. New York State Common Retirement Fund grew its position in shares of Catalyst Pharmaceuticals by 47.6% in the 1st quarter. New York State Common Retirement Fund now owns 74,994 shares of the biopharmaceutical company’s stock worth $179,000 after buying an additional 24,200 shares during the last quarter. Finally, Alps Advisors Inc. grew its position in shares of Catalyst Pharmaceuticals by 23.6% in the 1st quarter. Alps Advisors Inc. now owns 137,441 shares of the biopharmaceutical company’s stock worth $328,000 after buying an additional 26,262 shares during the last quarter. Hedge funds and other institutional investors own 53.28% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Featured Story: Understanding Relative Strength Index

Get a free copy of the Zacks research report on Catalyst Pharmaceuticals (CPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply